Publications by authors named "Martina Vandebroek"
Background: As the therapeutic landscape for inflammatory bowel disease (IBD) continues to expand, a need exists to understand how patients perceive and value different attributes associated with their disease as well as with current and emerging treatments. These insights can inform the development and regulation of effective interventions for IBD, benefiting various stakeholders including healthcare professionals, drug developers, regulators, Health Technology Assessment bodies, payers, and ultimately patients suffering from IBD. In response to this, the present patient preference study was developed with the aim to (1) determine the relative preference weights for IBD treatment and disease related attributes, and (2) explain how preferences may differ across patients with different characteristics (preference heterogeneity).
View Article and Find Full Text PDFIntroduction: Given the rapid increase in novel treatments for patients with multiple myeloma (MM), this patient preference study aimed to establish which treatment attributes matter most to MM patients and evaluate discrete choice experiment (DCE) and swing weighting (SW) as two elicitation methods for quantifying patients' preferences.
Methods: A survey incorporating DCE and SW was disseminated among European MM patients. The survey included attributes and levels informed by a previous qualitative study with 24 MM patients.
Article Synopsis
- The study investigated what multiple myeloma (MM) patients value most in their treatment options, acknowledging uncertainties about long-term side effects and treatment effectiveness.
- It involved a literature review, discussions with 24 patients from Belgium, Finland, Romania, and Spain, and analyzed their concerns about treatment expectations, side effects, and their impacts on daily life.
- Key patient concerns included life-threatening side effects leading to organ damage, debilitating symptoms affecting mobility and independence, and fears of temporary treatment benefits overshadowed by severe chronic issues.
What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population.
Appl Health Econ Health Policy
December 2019
Background: Debate on pricing and reimbursement of cancer medicines highlights the need to establish the value of cancer medicines.
Objective: This study aims to elicit the trade-offs in cancer medicine characteristics that the Belgian population is willing to make.
Methods: A discrete choice experiment used six attributes with three levels each, based on literature and focus group discussions.